|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single Nucleotide Polymorphisms (SNPs) of P53 Pro72Arg, MDM2 SNP309, P21 Ser31Arg, ER SNP594, HER2 Ile655Val, and FGFR2 rs2981582 have drawn attention as genetic factors associated with cancer risk.
|
31759353 |
2019 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Previous studies have suggested associations between variants in TP53 (R72P) and MDM2 (SNP309) and cancer risk.
|
17909070 |
2007 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Hence, this study explores the single and combined effects of cancer risk, age of onset and cancer type of three single nucleotide polymorphisms (SNPs)-TP53 Pro72Arg, MDM2 SNP285 and SNP309-already described as modifiers on TP53 mutation carriers but not properly investigated in LFS Suggestive patients.
|
26956143 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prostate adenocarcinoma is one of the leading causes of cancer related mortality in men but still limited knowledge is available about its associated functional SNPs including rs1042522 (Pro72Arg).
|
24935583 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The prognostic significance of the Arg72Pro polymorphism of the p53 tumour suppressor gene in cancer is controversial.
|
17400332 |
2007 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The germ-line polymorphisms TP53 Arg72Pro and MDM2 SNP309 T>G are risk factors for tumor development and affect response to chemotherapy and survival in several cancers, but their prognostic and predictive value in patients with high-grade osteosarcomas is not yet defined.
|
19451596 |
2009 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mouse models for the p53 R72P polymorphism have recently been developed but a role for this SNP in modifying cancer risk in response to viral and chemical carcinogens has yet to be established experimentally.
|
23475592 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To explore the impact of the p53 PIN3-Arg72Pro haplotype on colorectal adenoma formation and progression to cancer.
|
17374954 |
2006 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
p53 gene variants i.e.16 bp duplication in intron 3, Arg72Pro in exon 4 and G>A in intron 6 have been reported to modulate susceptibility to various malignancies.
|
23621193 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
|
24373920 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Previous studies have indicated that the <i>TP53</i> gene Arg72Pro (rs1042522 C>G) polymorphism is associated with susceptibility to various types of cancer.
|
28275206 |
2017 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prostate adenocarcinoma is one of the leading causes of cancer related mortality in men but still limited knowledge is available about its associated functional SNPs including rs1042522 (Pro72Arg).
|
24935583 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
As ionizing radiation (IR) treatment is often used in cancer therapy, we sought to test the physiological effects of IR in mouse models of the p53 R72P polymorphism.
|
28594296 |
2017 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The TP53 Arg 72 Pro polymorphism has been reported to be a risk factor for several types of cancer, but its association with pancreatic cancer has not been fully evaluated.
|
21468597 |
2011 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of them, a nonsynonymous polymorphism, Arg72Pro (rs1042522 C>G), has been most extensively studied for the association with cancer risk; however, few studies have investigated its effect on Wilms' tumor.
|
28260929 |
2017 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Codon 72 exon 4 polymorphism (Arg72Pro) of the p53 gene has been implicated in cancer risk.
|
15633234 |
2005 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Various studies have evaluated the association between p53 codon 72 G > C (rs1042522) polymorphism and risk of cancer.
|
24863946 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The <i>TP53</i> Arg72Pro (rs1042522 C>G) polymorphism has been reported to be associated with the risk of several types of adult cancers; however, its risk for pediatric cancers remains unclear.
|
31293648 |
2019 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this report is to determine frequencies and associations of p53 codon 72 arg/pro polymorphism with different types of cancer in Sudan. p53 codon72 arg/pro polymorphism distribution and allele frequencies in 264 samples of different types of cancers were investigated using PCR.
|
23053979 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among various polymorphic variants of TP53 gene, codon 72 polymorphism (Arg72Pro) has been found to be associated with cancer susceptibility, but only few studies have investigated their effect on bladder cancer risk.
|
21156242 |
2010 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The p53 Arg72Pro single-nucleotide polymorphism (SNP) was found to be associated with an increased risk of various malignancies.
|
21778786 |
2011 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis.
|
26320432 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
TP53 Arg72Pro polymorphism has been proposed to have some effects on host's susceptibility to cancer.
|
24375191 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Arg72Pro substitution did not associate with decreased risk of cancer.
|
17535973 |
2007 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Analysis of TP53 (rs1042522) showed a significantly higher frequency in cancer samples (OR=1.22, 95%CI=1.004-1.481, p-value=0.016) while differences in frequency were not significant within each group (p-value=0.070).
|
23534750 |
2013 |